ALK (F1174L)
Sign in to save this workspaceALK · Variant type: point · HGVS: p.F1174L
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Lorlatinib | 100.0% | 0.0% | 97.24 |
| 2 | Brigatinib | 100.0% | 0.0% | 82.96 |
| 3 | Repotrectinib | 99.8% | 0.3% | 84.21 |
| 4 | Gilteritinib | 99.7% | 0.3% | 88.97 |
| 5 | Alectinib | 99.5% | 0.5% | 95.49 |
| 6 | Ceritinib | 99.3% | 0.7% | 95.44 |
| 7 | Crizotinib | 99.0% | 1.0% | 91.39 |
| 8 | Entrectinib | 98.7% | 1.3% | 93.69 |
| 9 | Nintedanib | 95.1% | 4.9% | 90.23 |
| 10 | Sunitinib | 93.0% | 7.0% | 91.73 |
| 11 | Bosutinib | 91.3% | 8.7% | 87.22 |
| 12 | Osimertinib | 85.7% | 14.3% | 97.24 |
| 13 | Pacritinib | 80.1% | 19.9% | 88.64 |
| 14 | Pralsetinib | 77.5% | 22.5% | 93.43 |
| 15 | Ruxolitinib | 76.2% | 23.8% | 98.25 |
| 16 | Alpelisib | 75.6% | 24.4% | 97.22 |
| 17 | Baricitinib | 62.2% | 37.8% | 97.99 |
| 18 | Darovasertib | 54.5% | 45.5% | 96.99 |
| 19 | Defactinib | 51.0% | 49.0% | 92.68 |
| 20 | Tenalisib | 50.9% | 49.1% | 97.98 |
| 21 | Axitinib | 45.5% | 54.5% | 93.23 |
| 22 | Tepotinib | 45.0% | 55.0% | 99.75 |
| 23 | Lazertinib | 44.9% | 55.1% | 97.47 |
| 24 | Erlotinib | 42.2% | 57.8% | 99.75 |
| 25 | Afatinib | 41.7% | 58.3% | 98.50 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Lorlatinib | 100.0% | 97.2% | +2.8% |
| Brigatinib | 100.0% | 99.2% | +0.8% |
| Repotrectinib | 99.8% | 99.4% | +0.4% |
| Gilteritinib | 99.7% | 99.5% | +0.2% |
| Alectinib | 99.5% | 98.6% | +0.9% |
| Ceritinib | 99.3% | 98.3% | +1.1% |
| Crizotinib | 99.0% | 97.7% | +1.3% |
| Entrectinib | 98.7% | 98.8% | -0.2% |
| Nintedanib | 95.1% | 84.9% | +10.3% |
| Sunitinib | 93.0% | 87.7% | +5.4% |
| Bosutinib | 91.3% | 75.1% | +16.2% |
| Osimertinib | 85.7% | 80.5% | +5.2% |
| Pacritinib | 80.1% | 55.3% | +24.8% |
| Pralsetinib | 77.5% | 82.6% | -5.1% |
| Ruxolitinib | 76.2% | 52.1% | +24.1% |
| Alpelisib | 75.6% | 80.7% | -5.1% |
| Baricitinib | 62.2% | 46.4% | +15.9% |
| Darovasertib | 54.5% | — | — |
| Defactinib | 51.0% | — | — |
| Tenalisib | 50.9% | 45.2% | +5.7% |
| Axitinib | 45.5% | — | — |
| Tepotinib | 45.0% | — | — |
| Lazertinib | 44.9% | 46.3% | -1.4% |
| Erlotinib | 42.2% | — | — |
| Afatinib | 41.7% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| Neuroblastoma | Brain/CNS | ref |
| neuroblastoma_autonomic_ganglia | Brain/CNS | ref |
| mesothelioma_pleura | Lung | ref |
| carcinoma_kidney | Kidney | ref |
| carcinoma_lung | Lung | ref |
| neuroblastic_tumour_autonomic_ganglia | Brain/CNS | ref |
| carcinoma_skin | Skin | ref |
| ganglioneuroblastoma_autonomic_ganglia | Brain/CNS | ref |
| inflammatory_myofibroblastic_tumour_soft_tissue | Soft Tissue | ref |
| carcinoma_salivary_gland | Salivary Gland | ref |
| carcinoma_prostate | Prostate | ref |
| NBL-US | Brain/CNS | ref |
| NB | Brain/CNS | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 23.8ms